Trial Profile

A Phase 3, Randomized, Open-Label, Active-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease on Dialysis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Aug 2019 According to a FibroGen media release, the regulatory decision for Roxadustat in China is expected in the third quarter of 2019.
24 Jul 2019 Results assessing the efficacy and safety of roxadustat for the treatment of anemia in patients undergoing dialysis in China published in the New England Journal of Medicine
18 Dec 2018 According to an AstraZeneca media release, roxadustat has been approved in China by the National Medical Products Administration (NMPA) for the treatment of patients with anaemia caused by chronic kidney disease (CKD) that are on dialysis (haemodialysis or peritoneal dialysis).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com